.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Andreas von Deimling

Heidelberg, DE

University Hospital Heidelberg

Speaker

15/09/2023
09:00 – 09:30 25 Min. 5 Min.
Invited Talk
S15-OT-T1
Tumor proteomics in neuropathology

Further involvements

14/09/2023
ePoster
PS1-NO-A55
Characterisation of gene fusions in MYB(L1)-altered gliomas
14/09/2023
ePoster
eP-NO-A88
Epigenetic and genetic characterization of T-cell lymphomas
14/09/2023
13:21 – 13:27 4 Min. 2 Min.
ePoster Talk
PS1-NO-A55
Characterisation of gene fusions in MYB(L1)-altered gliomas
15/09/2023
18:10 – 18:20 7 Min. 3 Min.
Abstract Talk
S24-NO-A17
A novel type of IDH-wildtype glioma characterized by highly diffuse growth pattern, distinct epigenetic profile and relatively favorable prognosis
15/09/2023
18:20 – 18:30 7 Min. 3 Min.
Abstract Talk
S24-NO-A20
Epigenetically defined angiocentric gliomas may lack angiocentric growth and instead show a variety of growth patterns
15/09/2023
18:40 – 18:50 7 Min. 3 Min.
Abstract Talk
S24-NO-A19
Transcriptomic and epigenetic dissection of spinal ependymomas (SP-EPN) identifies clinically relevant subtypes enriched for tumors with and without NF2 mutation